In this episode, I’m joined by Shalin Shah, CEO of Marius Pharmaceuticals, to talk about the past, present, and future of testosterone replacement therapy (TRT). From the systemic decline in testosterone levels among younger men to the breakthrough FDA-approved oral testosterone Kyzatrex, this conversation explores what’s next for hormone optimization—and why it matters more than ever.Take a look and listen as we dive deep into the myths around oral testosterone, why SHBG levels matter, how testosterone therapy affects inflammation, cardiovascular risk, cognition, libido, and longevity, and why optimizing free testosterone—not just total T—is the true goal. Plus, we discuss clinical pearls for transitioning from injections or pellets to oral therapy, monitoring labs effectively, and future directions for female testosterone replacement.Whether you’re a clinician, a patient, or someone interested in living with more energy, drive, and clarity—this episode is a must-listen.🧠 About Shalin Shah:Shalin Shah is the Chief Executive Officer of Marius Pharmaceuticals, a company pioneering innovative therapies to address testosterone deficiency and cardiometabolic disease. With a background in economics, biotech leadership, and healthcare strategy, Shalin has become a leading advocate for rethinking how testosterone is tested, prescribed, and perceived. He’s also the founder of RethinkTestosterone.com, an educational platform for clinicians and patients aiming to shift the paradigm from symptom-based care to proactive, personalized hormone optimization.This episode is brought to you by Tides Health, formulating physician-grade peptide-based supplements designed for performance, recovery, and longevity.🛒 Shop now at yourtides.com — Use code DRJONES for 15% off your first order📍 Resources & Links:• Learn more about Kyzatrex: https://www.kyzatrex.com/• Rethink Testosterone: https://www.rethinktestosterone.com/• 📲 Follow Shalin Shah on Instagram: @TheMetabolicCEO⏱️ TIMESTAMPS: